Novartis AG
NYSE:NVSDrug Manufacturers - General
-$3.38 today
- Market cap
- $293.13B
- Beta
- 0.49
- P/E (TTM)
- 20.7
- EPS (TTM)
- $7.06
- Dividend yield
- 3.13%
Volume 2.75M
Average 1.56M
NVS Net Income
Bottom-line profit after all expenses, interest, and taxes.
Novartis AGNYSE: NVS
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income declines year over year
Q2 FY2026 net income of $3.27B fell 19.2% year over year, behind the -6.6% change in trailing-twelve-month net income. Sequentially, it rose 3.5% from the prior quarter. Over 3 fiscal years it compounded at +26.4% a year.
Context
- Net income amounted to 25.6% of revenue in FY2025, up 2.6 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 12 analysts of $17.42B (+24.0%) for the fiscal year ending Dec 2026, a step up from the +17.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $3.27B+3.5% QoQ
- Last fiscal yearDec 2025
- $14.06B+17.7% YoY
- LTMJun 2026
- $12.76B-6.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -19.2% | +10.1% | +29.3 pp |
| 1 year | +17.7% | +24.0% | +6.2 pp |
| 3-year CAGR | +26.4% | +14.6% | -11.8 pp |
| 5-year CAGR | +12.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 14.06B USD
- Year-over-year change
- +17.7%
- 4-year CAGR
- -12.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.06B | +17.7% |
| FY2024 | 2024-12-31 | 11.94B | -19.6% |
| FY2023 | 2023-12-31 | 14.85B | +113.5% |
| FY2022 | 2022-12-31 | 6.96B | -71.0% |
| FY2021 | 2021-12-31 | 24.02B | — |
Net Income vs competitors
How NVS compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6.6% is the 6th highest of 11, against a peer median of -15.5%.
- Net income amounts to 22.9% of revenue for NVS, versus a peer median of 15.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 116.44B DKK | +4.8% | +22.6% | 35.3% | |
| LTM Sep 2026 | $16.1B USD | -35.9% | +14.3% | 16.2% | |
| LTM Jun 2026 | $12.76B USD | -6.6% | +26.4% | 22.9% | |
| LTM Sep 2026 | $10.99B USD | +16.9% | +46.1% | 17.7% | |
| LTM Sep 2026 | $10.35B USD | +333.4% | -29.1% | 15.7% | |
| LTM Jun 2026 | $9.28B USD | +83.8% | +3.7% | 18.9% | |
| LTM Jun 2026 | £4.82B GBP | +40.8% | -27.4% | 14.5% | |
| LTM Jun 2026 | $4.33B USD | -59.7% | -37.2% | 6.8% | |
| LTM Jun 2026 | €3.96B EUR | -56.6% | -2.3% | 8.1% | |
| LTM Jun 2026 | $3.17B USD | -80.7% | +7.9% | 4.8% | |
| LTM Jun 2026 | -$3.24B USD | -151.3% | +22.8% | 10.6% | |
| Peer median (excluding NVS) | — | -15.5% | +5.8% | 15.1% | |
Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.97B | 43.46B | 46.66B | 51.72B | 54.81B |
| Cost of Revenue | 11.74B | 11.58B | 12.47B | 12.83B | 13.69B |
| Gross Profit | 32.24B | 31.88B | 34.19B | 38.9B | 41.12B |
| Gross Margin | 73.3% | 73.4% | 73.3% | 75.2% | 75.0% |
| Research & Development | 8.64B | 9.17B | 11.37B | 10.02B | 10.74B |
| Selling, General & Admin | 12.83B | 12.19B | 12.52B | 12.57B | 13.31B |
| Operating Expenses | 22.18B | 23.93B | 24.42B | 24.35B | 24.05B |
| Depreciation & Amortization | 5.6B | 6.71B | 8.28B | 6.07B | 5.35B |
| EBITDA | 30.91B | 14.68B | 18.26B | 20.72B | 22.99B |
| EBITDA Margin | 70.3% | 33.8% | 39.1% | 40.1% | 41.9% |
| Operating Income | 10.06B | 7.95B | 9.77B | 14.54B | 17.07B |
| Operating Margin | 22.9% | 18.3% | 20.9% | 28.1% | 31.2% |
| Interest Income | 71M | 377.74M | 629.24M | 567.68M | 374.91M |
| Interest Expense | 905M | 834.62M | 876.12M | 1.04B | 1.19B |
| Other Income / Expenses | 14.47B | (769M) | (646M) | (904M) | (638.25M) |
| Income Before Tax | 24.53B | 7.18B | 9.12B | 13.64B | 16.44B |
| Pre-Tax Margin | 55.8% | 16.5% | 19.6% | 26.4% | 30.0% |
| Income Tax Expense | 1.63B | 1.13B | 551M | 1.7B | 2.4B |
| Net Income | 24.02B | 6.96B | 14.85B | 11.94B | 14.06B |
| Net Margin | 54.6% | 16.0% | 31.8% | 23.1% | 25.6% |
| EPS (Basic) | 10.71 | 3.19 | 7.15 | 5.92 | 7.25 |
| EPS (Diluted) | 10.63 | 3.17 | 7.10 | 5.87 | 7.19 |
| Weighted Avg Shares | 2.24B | 2.18B | 2.08B | 2.02B | 1.94B |
| Weighted Avg Shares (Diluted) | 2.26B | 2.2B | 2.09B | 2.04B | 1.96B |
Novartis AG
NYSE:NVS
Intrinsic Alpha fair value
Locked
Current Price
$155.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.